Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life

Authors Roberta Annicchiarico, Alessia Federici, Carla Pettenati, Carlo Caltagirone

Published 15 January 2008 Volume 2007:3(6) Pages 1113—1123


Roberta Annicchiarico1, Alessia Federici1, Carla Pettenati2, Carlo Caltagirone3
1I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy; 2Centro Alzheimer, Ospedale di Passirana di Rho, Rho, Milan, Italy; 3Dipartimento Neurologia Università “Tor Vergata” di Roma, I.R.C.C.S. Fondazione Santa Lucia, Rome, Italy
Abstract: Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive and functional abilities associated with various behavioral disturbances. Its impact on public health and society as a whole is devastating. Slowing of the cognitive impairment, and improvements in disease duration, self-sufficiency and behavioral disturbances represent the best outcomes of pharmacologic therapy. Cholinesterase inhibitors (ChE-I) have been shown to be effective in treating the cognitive, behavioral, and functional deficits of AD. Rivastigmine is a dual inhibitor of both acetylcholine esterase (AChE) and butyrylcholinesterase (BuChE), enzymes involved in the hydrolysis of acetylcholine. Although this drug has been shown to be beneficial in patients with AD, its benefits are limited and their long-term effectiveness has not been well demonstrated.
Keywords: Alzheimer’s disease, drugs, therapy

Download Article [PDF]